Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5technology 3unknown 3
CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring
The CMS 2027 Advance Notice (released February 2026) proposes two changes that structurally alter MA economics:
anti payvidor legislation targets all insurer provider integration without distinguishing acquisition based arbitrage from purpose built care delivery
Two bills introduced in the 119th Congress would structurally prohibit the "payvidor" model -- insurers that also own or control care delivery:
Kaiser Permanentes 80 year tripartite structure is the strongest precedent for purpose built payvidor exemptions because any structural separation bill that captures Kaiser faces 12.5 million members and Californias entire healthcare infrastructure
Kaiser Permanente is the original payvidor, operating since 1945. Its regulatory history is the most instructive precedent for how structural separation legislation would play out in practice.
community co creation in animation production includes storyboard sharing script collaboration and collectible integration as specific mechanisms
The Claynosaurz-Mediawan production model implements community involvement through three specific mechanisms that go beyond consultation or voting:
youtube first distribution for major studio coproductions signals platform primacy over traditional broadcast windowing
Mediawan Kids & Family, a major European studio group, chose YouTube premiere for the Claynosaurz animated series before licensing to traditional TV channels and platforms. This deviates from the conventional distribution hierarchy where premium content launches on broadcast/cable first, then cascad
human in the loop clinical AI degrades to worse than AI alone because physicians both de skill from reliance and introduce errors when overriding correct outputs
The human-in-the-loop model -- where AI suggests and humans verify -- is the default safety architecture for clinical AI. But two lines of evidence suggest this model is fundamentally flawed rather than merely imperfect.
healthcare AI regulation needs blank sheet redesign because the FDA drug and device model built for static products cannot govern continuously learning software
Bob Wachter argues that the current regulatory framework for healthcare AI is a "square peg and round hole problem." The FDA model was built for drugs that remain chemically identical forever and devices with fixed specifications. AI systems that learn, update, and adapt continuously break every ass
human needs are finite universal and stable across millennia making them the invariant constraints from which industry attractor states can be derived
The research on human needs converges from multiple independent directions on a striking conclusion: fundamental human needs are finite, universal across cultures, and stable on timescales vastly longer than industry cycles. This makes needs the "physics" of industry analysis -- the constraints that
industries are need satisfaction systems and the attractor state is the configuration that most efficiently satisfies underlying human needs given available technology
Industries exist because humans have needs. This sounds obvious, but the implications are profound when combined with attractor state analysis. Carl Menger established the foundational axiom in 1871: value flows backward from consumer needs to producer goods, not forward from production costs to pri
AI compresses drug discovery timelines by 30 40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics
AI-discovered drug candidates entering clinical trials have grown exponentially: 3 in 2016, 17 in 2020, 67 in 2023, an estimated 173 by 2026. AI compresses preclinical candidate development from 3-4 years to 13-18 months and achieves 80-90% Phase I success rates compared to 40-65% for traditional co
AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review
Consumer wearables now generate continuous HR, HRV, SpO2, sleep staging, and activity data. Clinical workflows are designed for point-in-time measurements. A doctor knows how to act on a blood pressure reading but not on 30 days of continuous wrist-based blood pressure trend data. This gap is the ce
healthcare is a complex adaptive system requiring simple enabling rules not complicated management because standardized processes erode the clinical autonomy needed for value creation
Larsson, Clawson, and Howard argue that healthcare has become "a classic example of what system scientists term a complex adaptive system" -- and that the standard organizational response (standardized processes, KPIs, guidelines, compliance requirements) is precisely wrong. The compliance approach
ambient AI documentation reduces physician documentation burden by 73 percent but the relationship between automation and burnout is more complex than time savings alone
The ambient clinical documentation market reached $1.85B globally in 2024, growing at 28.7% annually to a projected $17.75B by 2033. Abridge leads with 100+ health systems including Johns Hopkins (6,700 clinicians), Mayo Clinic, and Memorial Sloan Kettering. Clinical results show 73% less after-hour
medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials
Medical LLMs have reached and surpassed human benchmarks: OpenEvidence scored 100% on USMLE, Med-PaLM 2 achieved 86.5% on MedQA, and GPT-4 outperformed ED resident physicians in diagnostic accuracy for structured internal medicine cases. But a UVA/Stanford/Harvard randomized trial found that physici
value based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk
As of the most recent HCP-LAN measurement, 59.5% of US healthcare payments are tied to value and quality in some form, while 40.5% remain pure fee-for-service. But the composition matters enormously: only 19.6% of payments are in risk-based arrangements, and just 14% flow through fully capitated mod
consumer CGMs are going mainstream as behavioral change tools not clinical diagnostics because real time glucose visibility changes food choices even without randomized trial evidence
The OTC CGM transition arrived in 2024-2025. Dexcom Stelo became the first OTC CGM (FDA-cleared March 2024), available on Amazon since May 2025 with 400,000+ app downloads. Abbott Lingo followed in June 2024, specifically targeting non-diabetics. Levels Health pairs prescription CGMs with coaching s
WHOOP subscription only wearable model generates $260M revenue but trails Oura at half the revenue and a third the valuation because fitness first positioning limits the addressable wellness market
WHOOP's subscription-only model (device included with $199-359/year membership) is a genuine business model experiment in consumer health hardware. Subscriptions grew 20x since 2020 and revenue reached $260M in 2025. The screenless wrist strap, strain/recovery depth, and aspirational athlete endorse
SDOH interventions show strong ROI but adoption stalls because Z code documentation remains below 3 percent and no operational infrastructure connects screening to action
The evidence for SDOH intervention ROI is increasingly strong: food insecurity programs average 85% ROI (range 1-287%), housing programs average 50% ROI (range 5-224%), and one integrated SDOH care model showed 6.9:1 ROI with significantly fewer ED visits at 30 and 60 days. Social isolation alone co
healthcare AI funding follows a winner take most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds
Global healthcare venture financing reached $60.4 billion in 2025, the strongest annual deployment in years, with digital health funding hitting $14.2 billion. But the headline number masks a deeply bifurcated market.
the physician role shifts from information processor to relationship manager as AI automates documentation triage and evidence synthesis
PwC projects $1 trillion in annual US healthcare spending will shift from administrative overhead and brick-and-mortar infrastructure to AI-driven, digital-first models by 2035. The value creation ranks: (1) documentation automation (most certain -- $1.85B ambient market growing 28.7% annually), (2)
OpenEvidence became the fastest adopted clinical technology in history reaching 40 percent of US physicians daily within two years
OpenEvidence is the breakout story in clinical AI. Developed by Harvard and MIT researchers, it operates across 10,000+ hospitals, handles 8.5 million clinical consultations per month, and was the first AI to score 100% on the USMLE. Strategic content partnerships with NEJM and JAMA ground its respo
four competing payer provider models are converging toward value based care with vertical integration dominant today but aligned partnership potentially more durable
The competitive landscape for value-based care is consolidating around four structural models:
gene editing is shifting from ex vivo to in vivo delivery via lipid nanoparticles which will reduce curative therapy costs from millions to hundreds of thousands per treatment
As of early 2026, 46 cell and gene therapies have FDA approval, with prices concentrated in the $2-4M range: Casgevy ($2.2M for sickle cell), Lyfgenia ($3.1M), Zolgensma ($2.1M for SMA), Hemgenix ($3.5M for hemophilia B). These are all ex vivo therapies -- harvest cells, edit them, reinfuse -- requi
GLP 1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035
The GLP-1 receptor agonist market reached $63-70 billion in 2025, with Eli Lilly's Mounjaro/Zepbound generating over $36 billion and Novo Nordisk's semaglutide products contributing another $48.9 billion. The market is projected to reach $250-315 billion by 2035 at 12.8-17.5% CAGR.
personalized mRNA cancer vaccines show sustained 49 percent reduction in melanoma recurrence after five years representing a genuinely novel therapeutic paradigm
The Moderna/Merck partnership on intismeran (mRNA-4157/V940) represents the most advanced non-COVID mRNA therapeutic and a genuinely novel approach to cancer treatment. The vaccine is manufactured individually for each patient: tumor DNA is sequenced, up to 34 neoantigens are selected, and personali
Page 64 of 73